Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer

Chen, Bin; Dai, De-Chang; Tang, Hailin; Chen, Xi; Ai, Xiaohong; Huang, Xiaojia; Wei-dong, Wang; Xie, Xiaoming

doi:10.7150/jca.16622

Cited by 39 publications

(39 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ALP is an enzyme routinely tested in blood for its diagnostic value in liver and bone diseases. Furthermore, according to previous studies, high ALP levels have been related with a worse prognosis in some malignancies . Despite its role as a biomarker in several diseases, our results show a large concentration of ALP in both types of aspirates without differences between them.…”

Section: Discussionsupporting

confidence: 64%

Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis

Trapero

Jover

Fernández-Montolí

et al. 2017

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 64%

Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis

Trapero

Jover

Fernández-Montolí

et al. 2017

American J Rep Immunol

View full text Add to dashboard Cite

show abstract

“…[ 8 ] Elevated pre-treatment levels of both alkaline phosphatase (ALP) and LDH are significantly associated with decreased disease-free survival and OS in triple negative BC. [ 9 ] A retrospective study has shown that high pre-treatment LDH or both ALP and LDH levels or stably high LDH levels during first line treatment are negative and independent prognostic factors in patients with MBC. [ 10 ] Carcinoma antigen (CA15-3) is a better predictive biomarker of BC recurrence than ALP, but the use of both biomarkers together can provide an even better early indicator of recurrence.…”

Section: Introductionmentioning

confidence: 99%

Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis

Long

Prijatelj

et al. 2020

Medicine

View full text Add to dashboard Cite

Rationale: Palbociclib (PAL) is a first-in-class selective inhibitor of the cyclin-dependent kinases 4 (CDK4) and CDK6 and is indicated for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in combination with fulvestrant (FUL) in postmenopausal women. Antrodia cinnamomea (AC), a well-known Chinese folk medicine in Taiwan, possesses numerous biological capabilities, most notably an anti-tumor effect. However, the clinical use of AC as complementary medicine combined with adjuvant therapy is unexplored. In this case report, we evaluated AC combined with PAL plus FUL to reduce the tumor burden in an MBC patient. Patient concerns: A Slovenian woman diagnosed with relapsed bone metastases of breast cancer (BC) was unable to undergo surgery and refused radiation therapy due to fear of side effects; she also feared the side effects of adjuvants. However, she was eager to live with a high quality of life. Diagnosis: Stage IV, HR-positive/HER2-negative BC with relapse of bone metastases. Interventions: After diagnosis of relapse of bone metastases, she received adjuvant with PAL plus FUL. Additionally, she chose to take AC orally (10 g/d). Outcomes: The pain was mostly relieved, and the side effects of adjuvant therapy reduced. Magnetic resonance imaging revealed reduction of tumor size at the fifth month of adjuvant therapy plus AC. After 14 months of adjuvant therapy plus AC, the tumors at the thoracic vertebrae T1 and T3 were found to have shrunk from 35.2 and 12.0 mm to 28.1 and 9.9 mm, respectively. Remarkably, no further metastases were observed. Lessons: According to the circulating tumor cells (CTCs) test data, AC had better anti-tumor efficacy on active tumor cells than PAL plus FUL. Thus, AC could be an effective complementary medicine for adjuvant therapy in patients with HR-positive/HER2-negative MBC. Interestingly, continued elevation of carcinoma antigen 15-3 and lactate dehydrogenase levels but decreasing levels of alkaline phosphatase were observed, which may be indicative of the potent efficacy of treatment resulting in massive tumor cell death. The CTCs test may be a sensitive approach to monitor the progression of BC and subsequently evaluate the efficiency of therapy.

show abstract

“…Recent studies have revealed that increased LDH is related to cancer progression in several solid tumors. [8][9][10][11][12][13][14]25 Several studies also have evaluated the prognostic value of LDH in ESCC. [15][16][17][18][19][20] Nevertheless, the prognostic role for pretreatment serum LDH in ESCC remains uncertain until now.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 Serum LDH, which is easily available in routine clinical practice, exists in various types of human tissue and neoplasms, and elevated LDH levels have traditionally been regarded as a marker of high tumor burden, which is a poor prognostic factor in various cancer. 7 Growing evidences have been contributed to explore the relationship between LDH and the progression of tumorigenesis in different malignancies, such as in lymphoma, 8 duodenum adenocarcinoma, 9 melanoma, 10 breast cancer, 11 nasopharyngeal carcinoma, 12 lung cancer, 13 pancreatic carcinoma. 14 Several investigators also scrutinized the prognostic value of LDH in ESCC.…”

Section: Introductionmentioning

confidence: 99%

A New Risk Score Model Based on Lactate Dehydrogenase Predicting Prognosis in Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy

Han

Zhou

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Purpose: The current study was to assess the prognostic value of the lactate dehydrogenase (LDH) in esophageal squamous cell cancer (ESCC) patients and to generate a risk score model to predict prognosis in patients who undergone chemoradiotherapy. Patients and Methods: 614 ESCC patients who received chemoradiotherapy were performed from 2012 to 2016.The optimal cutoff points for continuous variables were calculated by the X-tile program. We analyzed the association between LDH level and clinicopathological characteristics. And a 1:3 propensity score matching analysis was used to compensate for differences in baseline characteristics. The Kaplan-Meier methods and Cox regression models were used to explore the prognostic factors for overall survival (OS) and progression-free survival (PFS). Based on the results, we developed a corresponding risk score model and assessed its predictive capacity in the subgroups. Results: The optimal cutoff points of age, CEA, Cyfra21-1, tumor length, total dose and LDH were defined as follows:69 years, 2.4 ng/ml, 6.4 ng/ml, 6.5 cm, 58.8Gy and 134 U/L, respectively. A high level of LDH was associated with advanced M stage (p=0.005) and larger tumor length (p=0.026). Patients in the high-LDH group had shorter PFS and worse OS than those in the low-LDH group. Multivariate survival analysis indicated that pretreatment serum LDH level (p=0.039)，Cyfra21-1 level (p=0.003), tumor length (p=0.013), clinical N stage (p=0.047) and clinical M stage (p=0.011) were independent predictors for OS. Furthermore, a risk score model based on these five prognostic factors was established to divide patients into three groups with obvious prognosis (χ2 = 20.53, p< 0.0001). Conclusion: Pretreatment serum LDH levels may be a reliable factor in predicting the therapeutic effect of chemoradiotherapy in ESCC. A risk score model combined LDH, Cyfra21-1 and other prognostic factors could help to guide a personalized management. Further validation is needed before widely used in clinical practice.

show abstract

Pre-treatment serum alkaline phosphatase and lactate dehydrogenase as prognostic factors in triple negative breast cancer

Cited by 39 publications

References 44 publications

Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis

Analysis of the ectoenzymes ADA, ALP, ENPP1, and ENPP3, in the contents of ovarian endometriomas as candidate biomarkers of endometriosis

Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis

A New Risk Score Model Based on Lactate Dehydrogenase Predicting Prognosis in Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy

Contact Info

Product

Resources

About